Search
FILTERS
Services
Languages
Location
Ruby ZHOU, MD

Dr. Ruby ZHOU is a dermatologist at Jiahui Health. Dr. Zhou earned her bachelor degree of Medical Technology from Taiwan National Cheng Kung University and received medical degree of Dermatology and Cypridology from Peking University Health Science Center. She has over ten-year experience of general dermatosis, cosmetic laser and injection treatments for rejuvenation. She formerly worked as a dermatologist at The First Affiliated Hospital of Peking University, The First Affiliated Hospital of Fujian Medical University, Shanghai Landseed International Hospital and BDL-BASILICA Plastic & Cosmetic Center. She is experienced in applying comprehensive treatment to reconstitute youth and healthy skin with botulinum toxin, hyaluronic acid filler, chemical peeling, thread lifting and cosmetic techniques including laser, radiofrequency and focus ultrasound etc.
Dr. Ruby often engaged in cosmetic dermatology communication and academic activities in Korea, China and Taiwan. She is a member of Chinese Dermatologist Association, Chinese Association of Plastics and Aesthetics, China Cross-strait Association of Plastics and Aesthetics.
LicenseLicense no.no. :110110102005455:110110102005455
ZOU Shi 'en, MD, PhD

Currently, he is the Deputy Director of the Department of Gynecological Endocrinology and Reproductive Medicine, The Obstetrics and Gynecology Hospital of Fudan University, the Deputy Chairman of the Youth Committee of the Gynecology Branch of the Chinese Geriatrics Society, the Deputy Chairman of the Youth Committee of the Gynecology Branch of the Chinese Gerontology and Gerontology Society, and the member of the Endocrinology Group of the Gynecology Branch. Member of reproductive Endocrinology Professional Committee of China Medical Education Association, standing member of Menopause Training Center of Reproductive Endocrinology Professional Committee, member of Osteoporosis branch of Shanghai Medical Association, member of Scientific Popularization Branch of Shanghai Medical Doctor Association, member of National Health Science Popularization expert Bank.
Expertise
Minimally invasive treatment of gynecological benign and malignant tumors, including single-port and traditional laparoscopic surgery for uterine fibroids, ovarian cysts, cervical cancer and infertility. Diagnosis and treatment of diseases related to abnormal ovarian function, including polycystic ovary syndrome, premature ovarian failure, menopausal syndrome and menstrual disorders
Vic YAO, MD, PhD

Dr. Vic YAO currently serves as a Critical Care Medicine specialist in Jiahui International Hospital. Dr. Yao obtained his Doctor degree from Capital Medical University in 2012. From 2012 to 2022, he worded in the Department of critical care medicine of Shandong provincial hospital and completed the standardized training of critical care medicine residents and the standardized training of critical care medicine specialty, until he promoted to deputy chief physician. During this period, he participated in the compilation of two books Neurocritical Care and Practical Clinical Monitoring and Treatment of Acute and Critical Diseases, published 5 articles in Chinese or English core journals, and served as teaching or teaching tasks in National and Provincial critical care bronchoscopy and critical care ultrasound classes for many times, in the meanwhile he served as the secretary of Shandong Critical Care Medicine Quality Control Center. In 2022, Dr. Yao joined Jiahui as a member of the HDU team. Based on clinical front-line work experience and knowledge accumulation, Dr. Yao is familiar with theories and technologies related to intensive care and treatment, including ECMO, CRRT, critical bronchoscopy diagnosis and treatment technology, bedside critical ultrasound technology, hemodynamic monitoring technology, endotracheal intubation and mechanical ventilation, etc. He has dedicated his work to apply advanced critical care medicine related diagnosis and treatment technology to treat critically ill patients in an all-round way.
Dr. Yao is certified in Basic Life Support (BLS), Advanced Cardiac Life Support (ACLS) by American Heart Association (AHA), and the 5C Critical Care Specialist Qualification Certificate issued by the Critical Care Medicine Branch of the Chinese Medical Association.
Ferris LI, MD,PhD

Dr. Ferris LI is currently the Deputy Chief of Intensive Care Unit (ICU) in JiaHui International Hospital. Dr. Li obtained his Bachelor’s Degree of Clinical Medicine in 2002 and Master’s Degree of Cardiovascular Surgery in 2010 from Shanghai Jiaotong University School of Medicine. He obtained Doctorate Degree in 2022. Before joining Jiahui Health, Dr. Li worked in Shanghai Chest hospital for 18 years and completed residency in intensive care unit in that hospital. In 2012 and 2018, he completed the promotion of attending physician and deputy chief physician. During 2009 to 2021, Dr. Li published 13 articles in core journals, obtained one utility model patent led and participated two projects from National Natural Science Foundation of China, participated in the book of thoracic surgery and served on Critical Care Specialist of Shanghai Medical Association and Critical Care Specialist of Shanghai traditional Chinese Medicine Association. In 2021, Dr. Li joined Jiahui as a member of the HDU team. Dr. Li has mastered the theory and technology of critical care medicine, including perioperative management of cardiothoracic surgery, postoperative complication management and functional rehabilitation, and is responsible for the “three-basic” examination and Cardiopulmonary Resuscitation (CPR)training of the whole hospital.
Dr. Li is certified in Basic Life Support (BLS) and Advanced Cardiac Life Support (ACLS) by American Heart Association (AHA).
ZHAO Qinghua(Specialist), MD, PhD

Dr. ZHAO has 25 years of clinical experience in spine surgery and has personally performed more than 12,000 spinal operations. He is proficient in both open and minimally invasive surgical techniques for common and complex spinal disorders, with particular expertise in the standardized diagnosis and treatment of cervical spondylosis, ossification of the posterior longitudinal ligament of the cervical spine, spinal epidural lipomatosis, ossification of the thoracic ligamentum flavum, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, scoliosis, spinal tumors and spinal trauma.
Dr. ZHAO has visited the Department of Spine Surgery of Bordeaux University Hospital (France), the spine center of Charité – Universitätsmedizin Berlin (Germany), the Oberlinhaus Spine Center in Potsdam (Germany) and the Department of Spine Surgery of Aarhus University Hospital (Denmark) for academic exchange. He studied under Prof. Cody Bünger, former President of SICOT (International Society of Orthopaedic Surgery and Traumatology), Prof. Le Huec, President of the French Scoliosis Society, and Prof. Reinhardt, a renowned German spine surgeon.
Dr. ZHAO Qinghua is currently Chief Physician, Professor, Doctoral Supervisor and Postdoctoral Co-Supervisor in the Department of Spine Surgery at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. He also serves as Head of the SJTU Innovative Interdisciplinary Base for Bone Metabolism and Materials, and holds positions as deputy group head and committee member in several national academic societies, including the Chinese Medical Association, the Chinese Medical Doctor Association and the Chinese Association of Rehabilitation Medicine. In addition, he is appointed as a peer-review expert for projects of the National Natural Science Foundation of China, a review expert for national science and technology programs, and a correspondence reviewer of dissertations for the Academic Degree Center of the Ministry of Education.
In research, Dr. ZHAO has served as principal investigator of 6 national-level projects, including key special programs for intergovernmental international cooperation under the National Key R&D Program of China, key programs of China's Manned Space Engineering, international cooperation and exchange programs of the National Natural Science Foundation of China, and NSFC General Programs. As corresponding author, he has published more than 50 SCI papers in leading international journals such as Nature Metabolism. He has served as chief editor of 4 monographs and co-authored 8 others; his students have been granted 3 national-level science and technology innovation projects; and he holds 2 granted invention patents and 14 utility model patents.
Dr. ZHAO was selected for the Shanghai "Pujiang Talent Program" and the Excellent Young Teachers Cultivation Program of Shanghai universities. His honors include Shanghai Outstanding Figure in Health Science Popularization, Shanghai Outstanding Individual for Health Science Popularization Serving the Public, the "Innovation Star" of the Shanghai Starlight Program, Outstanding Mentor of the Shanghai Science and Technology Innovation Mayor's Award, and "Top Ten Class Mentors" of Shanghai Jiao Tong University School of Medicine.
He has also received the Best Innovative Research Award of the National Young Orthopaedic Surgeons Innovation Competition, the Best Innovative Research Award of the Chinese Research Hospital Association, the Second Prize of the Shanghai Science and Technology Progress Award, the First Prize of the Shanghai Outstanding Orthopaedic Paper Award, the First Prize of the Shanghai Staff Science and Technology Innovation Award, and the Second Prize of the Medical Education Research Achievement Award of Shanghai Jiao Tong University.
In the field of health science popularization, Dr. Zhao is dedicated to public education on orthopaedics and bone health. He has more than 3.5 million followers across platforms, with cumulative video views exceeding 250 million and over 15 million likes, and is committed to standardized, professional and accessible orthopaedic health communication.
WANG Liwei

Current Positions
•Chief Physician, Professor, Doctoral Supervisor
•Director of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
•Director, MDT Expert Committee, Renji Hospital
•MDT Team Leader for Cancers of Unknown Primary Origin & Multiple Primary Malignancies, Renji Hospital
•Director, Shanghai Jiao Tong University Pancreatic Cancer Diagnosis and Treatment Center
•Director, Oncology Clinical Drug Trial Base
•Consultant of Jiahui International Cancer Center
Clinical Expertise & Research Focus
•Personalized precision diagnosis and treatment of various complex and difficult tumors
•Translational research on gastrointestinal tumors, especially pancreatic cancer precision diagnosis and treatment
•Oncology multidisciplinary team (MDT) diagnosis and treatment
•Individualized targeted therapy and immunotherapy guided by clinical tumor genomics
•Special expertise in precision treatment models for cancers of unknown primary and multiple primary tumors
Academic Appointments
•Head, Pancreatic Tumor Group, Chinese Society of Oncology, Chinese Medical Association
•Council Member, Chinese Society of Clinical Oncology (CSCO)
•First Director, CSCO Pancreatic Cancer Expert Committee
•Council Member, China Anti-Cancer Association (CACA), and First Director, CACA Integrated Onco-Nephrology Committee
•Council Member, Shanghai Medical Association; Director, Oncology Internal Medicine Branch
•Vice Chairman, Shanghai Anti-Cancer Association; Director, Difficult Tumor Professional Committee
•President, Yangtze River Delta Cancer Specialty Alliance
•Leading Talent of Shanghai; Outstanding Academic Leader of Shanghai
Research Achievements
•Visiting researcher at UCLA and MD Anderson Cancer Center (2001–2004)
•Led development of China’s first Chinese Expert Consensus on Comprehensive Diagnosis and Treatment of Pancreatic Cancer
•Led development of the first CSCO Pancreatic Cancer Diagnosis and Treatment Guidelines
•Led development of the first CACA Technical Guidelines for the Protection of Cancer-Related Kidney Diseases
•Principal Investigator of 7 National Natural Science Foundation of China (NSFC) projects, including major research plans
•Principal Investigator of 2 major new drug creation projects and over 10 other fund projects
•Founded China’s first “Pancreatic Cancer Internet+ Consultation Platform” and “China Advanced Pancreatic Cancer Registry Platform”
•Published over 100 SCI-indexed papers with over 1,000 citations
•Associate Editor, Journal of Pancreatology; Editorial Board Member, Cancer Research, Journal of Hematology & Oncology (JHO), etc.
HAN Baohui

Professional Summary
Professor HAN Baohui has spent several decades in respiratory medicine clinical practice, teaching, and translational research, focusing on lung cancer multidisciplinary comprehensive care and novel biotherapy / targeted / anti-angiogenic strategies (including immune chemotherapy clinical exploration).
He is a State Council Special Allowance recipient and has led or co authored national level lung cancer guidance/consensus, e.g. the Chinese Expert Consensus on Anti angiogenic Drug Therapy for Advanced NSCLC, and has contributed to CMA/NCCN style guideline work referenced in Chinese scholarly publications.
Position & Affiliations
•Senior Consultant, Lung Cancer MDT Team, Jiahui International Cancer Center
•Emeritus Director, Dept. of Pulmonary and Critical Care Medicine, Shanghai Chest Hospital
•Professor / Doctoral Supervisor, Shanghai Jiao Tong University School of Medicine
•Consultant of Jiahui International Cancer Center
Clinical Expertise
•Complex/high risk lung cancer diagnosis and treatment
•Targeted therapy & resistance pathways, with ongoing work in EGFR Exon20ins and novel agent development
•Biotherapy/immunotherapy + anti angiogenic combinations, including clinical trial–based care pathways
Key Research & Drug Development Role
•Principal Investigator (PI) for several pivotal clinical studies supporting Furmonertinib (伏美替尼) and other domestically developed anti cancer agents; he is especially active in EGFR exon 20 insertion (Exon20ins) and broader targeted + immunotherapy combination pathways for advanced NSCLC.
•Longstanding leadership in drug clinical trial infrastructure: Director of Shanghai Chest Hospital’s Drug Clinical Trial Institution / GCP center; NMPA (formerly CFDA) review/expert panel roles in related contexts.
Professional & Society Appointments
•Member, International Association for the Study of Lung Cancer(IASLC)
•Member, American Society of Clinical Oncology(ASCO)
•Executive President / Executive Chair, Chinese Academy of Lung Cancer
•Executive Committee Member, Chinese Society of Clinical Oncology(CSCO)
•Vice Chair, CSCO NSCLC Committee
•Standing Committee Member, Chinese Medical Association (CMA) Cancer Committee
•National Medical Products Administration (NMPA)review/assessment expert
GUO Ye

Chief Physician; Deputy Chief of the Department of Oncology Medicine and Director of the Phase I Clinical Trial Center, East Hospital Affiliated to Tongji University
Consultant of Jiahui International Cancer Center
Prof. GUO Ye graduated from Shanghai Medical University in 1996 and obtained a Master's degree in Oncology from the Graduate School of Fudan University in 2003. In 2006, he completed systematic Clinical Fellow training in the Department of Medical Oncology-Hematology at the National University Hospital, Singapore. Prof. GUO worked in the Department of Medical Oncology at Fudan University Shanghai Cancer Center from 1996 to 2017, and since 2017 has been at Shanghai East Hospital, serving as Deputy Chief of the Department of Oncology Medicine and Director of the Phase I Clinical Trial Center. He has published more than 20 papers in SCI-indexed journals.
Clinical Expertise
Medical treatment of head and neck cancers
Medical treatment of lymphoma
Academic Appointments
Deputy Secretary-General, Chinese Society of Clinical Oncology (CSCO)
Chairman, Head and Neck Cancer Committee, Chinese Society of Clinical Oncology (CSCO)
Vice Chairman, Thyroid Cancer Committee, Chinese Society of Clinical Oncology (CSCO)
Vice Chairman, Head and Neck Cancer Committee, Chinese Medical Doctor Association
Standing Committee Member, Lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO)
Vice Chairman, Youth Committee, Tumor Chemotherapy Committee, China Anti-Cancer Association
Member, Head and Neck Cancer Committee, China Anti-Cancer Association
Member, Nasopharyngeal Cancer Committee, China Anti-Cancer Association
Member, Lymphoma Committee, China Anti-Cancer Association
Vice Chairman, Head and Neck Cancer Committee, Shanghai Anti-Cancer Association
Vice Chairman, Lymphoma Committee, Shanghai Anti-Cancer Association
CHEN Jie

Director of Neuroendocrine Tumor Center and Director of Department of Neuroendocrine Tumor, Fudan University Shanghai Cancer Center; Chief Physician, Professor, Doctoral Supervisor; Chief Expert, Neuroendocrine Tumor Multidisciplinary Team
Consultant of Jiahui International Cancer Center
Education
Graduated from West China University of Medical Sciences, School of Clinical Medicine, in 1994
Twice a visiting scholar at the Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, during postgraduate studies (2000–2002)
Received MD in Gastroenterology from the First Affiliated Hospital of Sun Yat-sen University in 2002
Postdoctoral research at the Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Germany (2002–2004), focusing on the pathogenesis of gastrointestinal tumors
Studied neuroendocrine tumor diagnosis and treatment at Churchill Hospital, University of Oxford, and Royal Free Hospital / King's College Hospital, University of London (November–December 2011)
Clinical Expertise
Diagnosis and treatment of various neuroendocrine tumors, including:
-Neuroendocrine tumors of various sites and types: gastric and intestinal NETs, pancreatic NETs, gastrinoma, insulinoma, glucagonoma, carcinoid syndrome, ACTHoma, VIPoma, carcinoid, atypical carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, pheochromocytoma, paraganglioma, medullary thyroid carcinoma, cutaneous Merkel cell carcinoma, etc.
-Hereditary neuroendocrine tumors: multiple endocrine neoplasia types 1, 2 and 4 (MEN1/2/4), von Hippel-Lindau (VHL) syndrome, neurofibromatosis type 1 (NF1), etc.
Academic Contributions & Appointments
Since 2010, pioneered the field of neuroendocrine tumors (NEN) in China and established a comprehensive clinical diagnosis and treatment system, including a multidisciplinary team covering all NEN-related disciplines, dedicated medical groups, wards and clinics, with an annual outpatient volume of 4,500 visits
Selected in 2015 as the only Asian member of the ENETS Advisory Board, European Neuroendocrine Tumor Society
In 2015, the Chinese Study Group for Neuroendocrine Tumor (CSNET) under the Pancreatic Cancer Committee of China Anti-Cancer Association was established, and she served as its first group leader
Invited in 2019 as an editorial board member of Neuroendocrinology, the official journal of ENETS
Invited in 2020 as a member of the Medical Advisory Board of the International Neuroendocrine Cancer Alliance (INCA)
Invited in 2021 as a member of the Neuroendocrine and Endocrine Tumors Group of the European Society for Medical Oncology (ESMO), the first and only Chinese expert to serve on this committee
Initiated the establishment of the Neuroendocrine Tumor Committee of the China Anti-Cancer Association in 2022 and will serve as its first chairman
Member, Chinese Medical Association
Vice Chairman, Tumor Endocrinology Committee, China Anti-Cancer Association
Deputy Head, Gastrointestinal Hormone and Neuroendocrine Tumor Group, Digestive Disease Branch, Chinese Medical Association
Vice Chairman, Pancreatic Neuroendocrine Tumor Committee, Pancreatic Disease Branch, Chinese Medical Doctor Association
Standing Committee Member, Neuroendocrine Tumor Branch, China International Exchange and Promotive Association for Medical and Health Care
Member, Rare Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Senior Editorial Board Member, Journal of Neuroendocrinology; Editorial Board Member, Journal of Pancreatology; Editorial Board Member, China Oncology; Corresponding Editorial Board Member, Chinese Journal of Digestion
Research Achievements
Published more than 40 SCI-indexed clinical research papers, over 30 as corresponding author or co-corresponding/first author, covering epidemiology, molecular markers, drug therapy, imaging diagnosis, and pathological grading and staging
A multicenter collaborative study on modified staging of pancreatic neuroendocrine tumors was published in the top oncology journal J Clin Oncol
As CSNET group leader, initiated and participated in the development of two CSNET expert consensuses, published in Int J Oncol in 2016–2017
As a major contributor, participated in the development of the Expert Consensus on Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Tumors (Digestive Disease Branch, Chinese Medical Association) and the Guidelines for Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors (Pancreatic Surgery Group, Surgery Branch, Chinese Medical Association)
As chief editor, led the development of the first Integrated Diagnosis and Treatment Guidelines for Neuroendocrine Tumors of the China Anti-Cancer Association
As a member of the ENETS Advisory Board, participated in the development of the 2017 updated ENETS clinical practice guidelines for neuroendocrine tumors
FANG Rui(Specialist), MD, PhD

Dr. FANG Rui serves as the multi-site practice physician at Jiahui Health.
Chief Physician, Master’s Supervisor, PhD
Vice Director of the Department of Laryngology, Sleep-disordered Breathing Center and Voice Center, Eye & ENT Hospital of Fudan University
He is experienced in the diagnosis and treatment of a full spectrum of otolaryngological disorders. His main clinical and research focuses are as follows:
- Precision diagnosis and management of laryngeal and voice disorders
- Minimally invasive surgery for tonsillar hypertrophy, adenoid hypertrophy and chronic tonsillitis
- Comprehensive evaluation and surgical treatment of obstructive sleep apnea hypopnea syndrome (snoring disease)
- Minimally invasive and laser surgery for laryngeal cancer, hypopharyngeal cancer, epiglottic cancer and pharyngeal papilloma
- Phonomicrosurgery for vocal fold leukoplakia, vocal fold polyp, epiglottic cyst, laryngeal papilloma, laryngeal hemangioma and pharyngeal hemangioma
- Diagnosis and management of vocal fold paralysis, spasmodic dysphonia, arytenoid dislocation, laryngeal stenosis and vocal fold adhesion
Professional Appointments:
Standing Committee Member, Voice Subcommittee, Otorhinolaryngology Branch, Chinese Association of Integrated Traditional and Western Medicine
Member, Interventional Oncology Section, Shanghai Medical Association
- First page
- Previous page
- ...
- 18
- 19
- 20
- 21
- 22
- ...
- Next page
- Last page









